New York State Common Retirement Fund’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-729
Closed 3525
2022
Q2
$0 Sell
729
-41,000
-98% -$31.5K ﹤0.01% 3573
2022
Q1
$48K Hold
41,729
﹤0.01% 3180
2021
Q4
$94K Sell
41,729
-207
-0.5% -$520 ﹤0.01% 3092
2021
Q3
$143K Sell
41,936
-33,064
-44% -$102K ﹤0.01% 3026
2021
Q2
$224K Buy
+75,000
New +$237K ﹤0.01% 3004
2017
Q2
Sell
-44,801
Closed -$145K 3257
2017
Q1
$145K Buy
44,801
+1
+0% +$2 ﹤0.01% 2877
2016
Q4
$60K Hold
44,800
﹤0.01% 3044
2016
Q3
$70K Hold
44,800
﹤0.01% 3045
2016
Q2
$60K Hold
44,800
﹤0.01% 3073
2016
Q1
$236K Hold
44,800
﹤0.01% 2604
2015
Q4
$352K Hold
44,800
﹤0.01% 2474
2015
Q3
$379K Sell
44,800
-8,282
-16% -$76.4K ﹤0.01% 2442
2015
Q2
$581K Buy
53,082
+32,132
+153% +$412K ﹤0.01% 2443
2015
Q1
$293K Buy
+20,950
New +$320K ﹤0.01% 2107

Other funds holding INFI

New York State Common Retirement Fund's INFI Position: Q3 2022 in Review

New York State Common Retirement Fund sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q3 2022, closing a stake of 729 shares.

New York State Common Retirement Fund first reported a position in INFI in Q1 2015 and held it in 14 quarters. The position peaked at $581K in Q2 2015. 76 funds tracked by Wall St. Rank hold INFI as of Q3 2022.

  • New York State Common Retirement Fund reported no remaining Infinity Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
  • New York State Common Retirement Fund sold 729 Infinity Pharmaceuticals, Inc. shares in Q3 2022.
  • New York State Common Retirement Fund first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2015 and held it in 14 quarters.
  • New York State Common Retirement Fund's Infinity Pharmaceuticals, Inc. position peaked at $581K in Q2 2015.
  • 76 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q3 2022.

Based on New York State Common Retirement Fund's 13F filing for Q3 2022, filed 8 Nov 2022.